Cargando…

Deciphering mechanisms of drug sensitivity and resistance to Selective Inhibitor of Nuclear Export (SINE) compounds

BACKGROUND: Exportin 1 (XPO1) is a well-characterized nuclear export protein whose expression is up-regulated in many types of cancers and functions to transport key tumor suppressor proteins (TSPs) from the nucleus. Karyopharm Therapeutics has developed a series of small-molecule Selective Inhibito...

Descripción completa

Detalles Bibliográficos
Autores principales: Crochiere, Marsha, Kashyap, Trinayan, Kalid, Ori, Shechter, Sharon, Klebanov, Boris, Senapedis, William, Saint-Martin, Jean-Richard, Landesman, Yosef
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2015
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4647283/
https://www.ncbi.nlm.nih.gov/pubmed/26573568
http://dx.doi.org/10.1186/s12885-015-1790-z
_version_ 1782401066813358080
author Crochiere, Marsha
Kashyap, Trinayan
Kalid, Ori
Shechter, Sharon
Klebanov, Boris
Senapedis, William
Saint-Martin, Jean-Richard
Landesman, Yosef
author_facet Crochiere, Marsha
Kashyap, Trinayan
Kalid, Ori
Shechter, Sharon
Klebanov, Boris
Senapedis, William
Saint-Martin, Jean-Richard
Landesman, Yosef
author_sort Crochiere, Marsha
collection PubMed
description BACKGROUND: Exportin 1 (XPO1) is a well-characterized nuclear export protein whose expression is up-regulated in many types of cancers and functions to transport key tumor suppressor proteins (TSPs) from the nucleus. Karyopharm Therapeutics has developed a series of small-molecule Selective Inhibitor of Nuclear Export (SINE) compounds, which have been shown to block XPO1 function both in vitro and in vivo. The drug candidate, selinexor (KPT-330), is currently in Phase-II/IIb clinical trials for treatment of both hematologic and solid tumors. The present study sought to decipher the mechanisms that render cells either sensitive or resistant to treatment with SINE compounds, represented by KPT-185, an early analogue of KPT-330. METHODS: Using the human fibrosarcoma HT1080 cell line, resistance to SINE was acquired over a period of 10 months of constant incubation with increasing concentration of KPT-185. Cell viability was assayed by MTT. Immunofluorescence was used to compare nuclear export of TSPs. Fluorescence activated cell sorting (FACS), quantitative polymerase chain reaction (qPCR), and immunoblots were used to measure effects on cell cycle, gene expression, and cell death. RNA from naïve and drug treated parental and resistant cells was analyzed by Affymetrix microarrays. RESULTS: Treatment of HT1080 cells with gradually increasing concentrations of SINE resulted in > 100 fold decrease in sensitivity to SINE cytotoxicity. Resistant cells displayed prolonged cell cycle, reduced nuclear accumulation of TSPs, and similar changes in protein expression compared to parental cells, however the magnitude of the protein expression changes were more significant in parental cells. Microarray analyses comparing parental to resistant cells indicate that a number of key signaling pathways were altered in resistant cells including expression changes in genes involved in adhesion, apoptosis, and inflammation. While the patterns of changes in transcription following drug treatment are similar in parental and resistant cells, the extent of response was more robust in the parental cells. CONCLUSIONS: These results suggest that SINE resistance is conferred by alterations in signaling pathways downstream of XPO1 inhibition. Modulation of these pathways could potentially overcome the resistance to nuclear export inhibitors. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (doi:10.1186/s12885-015-1790-z) contains supplementary material, which is available to authorized users.
format Online
Article
Text
id pubmed-4647283
institution National Center for Biotechnology Information
language English
publishDate 2015
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-46472832015-11-18 Deciphering mechanisms of drug sensitivity and resistance to Selective Inhibitor of Nuclear Export (SINE) compounds Crochiere, Marsha Kashyap, Trinayan Kalid, Ori Shechter, Sharon Klebanov, Boris Senapedis, William Saint-Martin, Jean-Richard Landesman, Yosef BMC Cancer Research Article BACKGROUND: Exportin 1 (XPO1) is a well-characterized nuclear export protein whose expression is up-regulated in many types of cancers and functions to transport key tumor suppressor proteins (TSPs) from the nucleus. Karyopharm Therapeutics has developed a series of small-molecule Selective Inhibitor of Nuclear Export (SINE) compounds, which have been shown to block XPO1 function both in vitro and in vivo. The drug candidate, selinexor (KPT-330), is currently in Phase-II/IIb clinical trials for treatment of both hematologic and solid tumors. The present study sought to decipher the mechanisms that render cells either sensitive or resistant to treatment with SINE compounds, represented by KPT-185, an early analogue of KPT-330. METHODS: Using the human fibrosarcoma HT1080 cell line, resistance to SINE was acquired over a period of 10 months of constant incubation with increasing concentration of KPT-185. Cell viability was assayed by MTT. Immunofluorescence was used to compare nuclear export of TSPs. Fluorescence activated cell sorting (FACS), quantitative polymerase chain reaction (qPCR), and immunoblots were used to measure effects on cell cycle, gene expression, and cell death. RNA from naïve and drug treated parental and resistant cells was analyzed by Affymetrix microarrays. RESULTS: Treatment of HT1080 cells with gradually increasing concentrations of SINE resulted in > 100 fold decrease in sensitivity to SINE cytotoxicity. Resistant cells displayed prolonged cell cycle, reduced nuclear accumulation of TSPs, and similar changes in protein expression compared to parental cells, however the magnitude of the protein expression changes were more significant in parental cells. Microarray analyses comparing parental to resistant cells indicate that a number of key signaling pathways were altered in resistant cells including expression changes in genes involved in adhesion, apoptosis, and inflammation. While the patterns of changes in transcription following drug treatment are similar in parental and resistant cells, the extent of response was more robust in the parental cells. CONCLUSIONS: These results suggest that SINE resistance is conferred by alterations in signaling pathways downstream of XPO1 inhibition. Modulation of these pathways could potentially overcome the resistance to nuclear export inhibitors. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (doi:10.1186/s12885-015-1790-z) contains supplementary material, which is available to authorized users. BioMed Central 2015-11-17 /pmc/articles/PMC4647283/ /pubmed/26573568 http://dx.doi.org/10.1186/s12885-015-1790-z Text en © Crochiere et al. 2015 Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
spellingShingle Research Article
Crochiere, Marsha
Kashyap, Trinayan
Kalid, Ori
Shechter, Sharon
Klebanov, Boris
Senapedis, William
Saint-Martin, Jean-Richard
Landesman, Yosef
Deciphering mechanisms of drug sensitivity and resistance to Selective Inhibitor of Nuclear Export (SINE) compounds
title Deciphering mechanisms of drug sensitivity and resistance to Selective Inhibitor of Nuclear Export (SINE) compounds
title_full Deciphering mechanisms of drug sensitivity and resistance to Selective Inhibitor of Nuclear Export (SINE) compounds
title_fullStr Deciphering mechanisms of drug sensitivity and resistance to Selective Inhibitor of Nuclear Export (SINE) compounds
title_full_unstemmed Deciphering mechanisms of drug sensitivity and resistance to Selective Inhibitor of Nuclear Export (SINE) compounds
title_short Deciphering mechanisms of drug sensitivity and resistance to Selective Inhibitor of Nuclear Export (SINE) compounds
title_sort deciphering mechanisms of drug sensitivity and resistance to selective inhibitor of nuclear export (sine) compounds
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4647283/
https://www.ncbi.nlm.nih.gov/pubmed/26573568
http://dx.doi.org/10.1186/s12885-015-1790-z
work_keys_str_mv AT crochieremarsha decipheringmechanismsofdrugsensitivityandresistancetoselectiveinhibitorofnuclearexportsinecompounds
AT kashyaptrinayan decipheringmechanismsofdrugsensitivityandresistancetoselectiveinhibitorofnuclearexportsinecompounds
AT kalidori decipheringmechanismsofdrugsensitivityandresistancetoselectiveinhibitorofnuclearexportsinecompounds
AT shechtersharon decipheringmechanismsofdrugsensitivityandresistancetoselectiveinhibitorofnuclearexportsinecompounds
AT klebanovboris decipheringmechanismsofdrugsensitivityandresistancetoselectiveinhibitorofnuclearexportsinecompounds
AT senapediswilliam decipheringmechanismsofdrugsensitivityandresistancetoselectiveinhibitorofnuclearexportsinecompounds
AT saintmartinjeanrichard decipheringmechanismsofdrugsensitivityandresistancetoselectiveinhibitorofnuclearexportsinecompounds
AT landesmanyosef decipheringmechanismsofdrugsensitivityandresistancetoselectiveinhibitorofnuclearexportsinecompounds